創薬流通市場「薬市楽座」
安土桃山時代に自由取引市場として発展した「楽市楽座」にあやかり、創薬シーズ・技術のマーケットプラットフォームを創薬流通市場、「薬市楽座」と名付けました。このマーケットが楽市楽座のように発展することを願っています。
創薬流通市場である薬市楽座では、弊社がお預かりしている創薬シーズ・技術の情報をリストアップしています。ご興味に応じて検索していただくことが可能です。また、リストのダウンロードも行っていただけます。ご興味のあるものがあれば、お問い合わせボタンをクリックしていただき、弊社へのコンタクトをお願いいたします。追加情報を開示させていただきます。
なお、2019年6月27日より、日本語ページにおける、創薬シーズ、創薬技術の各リスト表記が英語に変更になりました。ダウンロード用のPDF、エクセルファイルは英語ページよりダウンロードできる資料と同一ですので、予めご了承下さいませ。
| 掲載日 | シーズ番号 | 作用機序 | 適応症 | 投与経路 | モダリティ | 開発ステージ | 備考 | |
|---|---|---|---|---|---|---|---|---|
| 19/07/16 | GEM091 | Prevention of protein aggregation via increased intracellular ATP and increase of expression of tyrosine hydroxylase (TH) | Parkinson's disease | Oral/nasal | Small molecules |
Preclinical | New treatment for Parkinson's disease. GEM091 increases intracellular ATP level and ATP is reported to boost protein solubility. GEM091 increases TH expression and dopamine production, reverses paraquat induced PD symptoms and improves behavior of 6-OHDA treated mice. | 問合せ |
| 19/07/16 | GEM090 | Increase cellular ATP and promote wound healing | Refer to Note | Topical | Small molecules |
Preclinical | Indication: Epidermolysis Bullosa (EB) Increasing cellular ATP and speeding up the healing of wounds by promoting the migration of epithelia cells in the skin of wounds. Expected to shorten wound healing time and improve EB patients' QOL with a formulation optimized for EB treatment. Moreover, maybe reduces the risk of squamous cell carcinoma which is highly related to Dystrophic EB patients. |
問合せ |
| 19/07/12 | GEM089 | Inhibition of pro-cytokines, enhancement of growth factor PDGF | Alzheimer's disease and vascular dementia | Topical | Botanical |
Phase 2 | Small molecules from soybean extract. MOA is different from Tau and Amyloid mechanisms. Effective in AlCl3 induced Alzheimer-like dementia model and bilateral common carotid artery occlusion induced vascular dementia model. In Phase 2 study, MMSE and ADAS-Cog for patients without any dementia medication indicated that 70-85% patients improved at weeks 4 and 12. |
問合せ |
| 19/07/12 | GEM088 | SSRI with agonist-antagonistic action on 5-HT receptors | Urinary incontinence | Oral | Small molecule |
Phase 3 ready | Repositioning from another indication and has already a proven record of good safety in more than 300 patients with further 300 treated in phase 2. It has shown therapeutic activity in animal models of both stress and urge urinary incontinence. In phase 2 trials, clinically meaningful effects in mixed incontinence were shown as well as very good tolerability. The compound is ready to enter phase 3. |
問合せ |
| 19/07/08 | GEM087 | Corticosteroid receptor agonist | Refer to Note | Refer to Note | Small molecule |
Preclinical | Indication: Ocular inflammation and Meibomian gland dysfunction (MGD) Route: Topical (eye drop) New ophthalmic suspension of loteprednol etabonate (LE) with improved ocular bioavailability. - Drug exposure in aqueous humor and iris ciliary body are about 6 fold higher than Lotemax® in rabbits. - The new formulation of LE administered twice a day for the treatment of adjuvant induced chronic uveitis model in rabbits showed a similar efficacy with lotemax administered four times a day |
問合せ |
| 19/07/08 | GEM086 | VEGF inhibitor | Refer to Note | Refer to Note | Small molecule |
Preclinical | Indication: Wet AMD (age-related macular degeneration) Route: Topical (eye drop) New formulation of axitinib designed to deliver the drug across ocular tissues to choroid and retina. -Greatly enhancing aqueous solubility (4000-fold solubility enhancement) - High drug exposure in retina (300-fold of IC50) - Potential for substitution of anti-VEGF Ab treatment via intravitreal injection |
問合せ |
| 19/07/08 | GEM085 | Anti-Her2 antibody drug conjugates (ADCs) | Cancers with moderate to high Her2 expression | IV | Protein |
Preclinical | The anti-Her2 ADCs consiting of trastuzumab and novel linker-drugs. - 10-100 fold higher potency comparting to Kadcyla® - High theraperutic window (MED ~1-2 mg/kg, MTD ~100 mg/kg in mice) - High tumor growth inhibition rate (90-100%) with high stability in vivo |
問合せ |
| 19/07/04 | GEM084 | MRI contrast agent formulation | Diagnosis of bladder cancer | see Note | Others |
Phase 2 ready | Route: Topical (Intravesical) New formulation consisting of iron and gadolinium for intravesical instillation. A pilot trial in humans provided evidence that the MRI contrast agent can be detected in the bladder wall. No treatment-related AEs were observed. |
問合せ |
| 19/07/04 | GEM083 | Vasoconstriction and anti-inflammatory action | Hemorrhagic Cystitis | see Note | Small molecule |
Phase 2 | Route: Topical (Intravesical) Pre-liposomal lyophilate containing tacrolimus. POC achieved in animal models of both chemo-cystitis and radiation cystitis. POC achieved in first-in-man experience treating severe recurrent hemorrhagic cystitis. Orphan drug designation granted. |
問合せ |
| 19/06/27 | GEM082 | Modified IL-1 receptor antagonist (IL-1RA) | Refer to Note | Intra-articular | Protein |
Preclinical | Indication: Osteoarthritis, gout, anterior cruciate ligament (ACL) injury Single intra-articular injection of Anakinra (rhIL-1RA) improved OA symptoms vs placebo in clinical Phase-2 but the effect was short-lasting. GEM082 showed prolonged retention in the joint and sustained efficacy. GEM082 targets directly the biology of the inflammasome, involved in acute OA pain flares, without the adverse effects of steroids. Avaliable for licensing to Japan, China and Taiwan. |
問合せ |